[Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].
OBJECTIVE
To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in combination with cyclosporine A (CsA) and methotrexate (MTX) for prevention of acute graft versus host disease (GVHD) after unrelated donor allogeneic bone marrow transplantation (allo-BMT).


METHODS
Twelve cases of unrelated donor allo-BMT were evaluated in a single center trial. The acute GVHD was prevented with 1 g MMF daily in addition to CsA 3 mg x kg(-1) x (-1) and MTX 10 - 15 mg at post BMT day1, day3, day6 and day11.


RESULTS
Acute GVHD was found in one case (Grade IV) at the seventh day and two cases (Grade II) at the tenth day and seventeenth day after BMT. These patients were treated with a combination of MMF, methyprednisolone and CsA. The common adverse hematologic events of MMF was leukopenia.


CONCLUSIONS
The preliminary study showed that MMF could be used effectively and safely for prevention of acute GVHD in unrelated donor allo-BMT.
Huang
H
H
Department of Hematology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, China.
Lin
M
M
Meng
H
H
Qian
W
W
Jin
J
J
Huang
J
J
Luo
Y
Y
D000208:Acute Disease / Q000628:therapy; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014183:Transplantation, Heterologous / Q000009:adverse effects*; D055815:Young Adult
D016572:Cyclosporine; D009173:Mycophenolic Acid; D008727:Methotrexate